ArticleJournal of cellular and molecular medicine2022

Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.

Haige Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.